Get the Stockscreener App
14.92
0.86%
-0.13
After Hours:
14.92
Nurix Therapeutics Inc stock is traded at $14.92, with a volume of 1.20M.
It is down -0.86% in the last 24 hours and down -5.51% over the past month.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
See More
Previous Close:
$15.05
Open:
$14.87
24h Volume:
1.20M
Relative Volume:
1.04
Market Cap:
$1.53B
Revenue:
$83.98M
Net Income/Loss:
$-264.46M
P/E Ratio:
-4.9045
EPS:
-3.0421
Net Cash Flow:
$-263.47M
1W Performance:
-4.42%
1M Performance:
-5.51%
6M Performance:
+76.78%
1Y Performance:
+7.34%
1-Day Range:
$14.60
$15.41
1-Week Range:
$14.60
$16.11
52-Week Range:
$8.18
$22.50
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Name
Nurix Therapeutics Inc
Sector
Industry
Phone
(415) 660-5320
Address
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
14.92 | 1.55B | 83.98M | -264.46M | -263.47M | -3.0421 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-24-25 | Resumed | Truist | Buy |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Mar-17-25 | Initiated | Leerink Partners | Market Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | Jefferies | Buy |
| Sep-06-24 | Resumed | Robert W. Baird | Outperform |
| Jul-31-24 | Initiated | Truist | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Mar-09-23 | Initiated | Barclays | Overweight |
| Feb-28-23 | Initiated | Oppenheimer | Outperform |
| Oct-11-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Feb-10-22 | Initiated | Wells Fargo | Equal Weight |
| Dec-29-21 | Initiated | H.C. Wainwright | Buy |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-30-21 | Resumed | Piper Sandler | Overweight |
| Apr-30-21 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Nov-19-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Needham | Buy |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | Stifel | Buy |
View All
Nurix Therapeutics Inc Stock (NRIX) Latest News
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million - AOL.com
Investment Recap: Is Nurix Therapeutics Inc undervalued by DCF analysisGap Up & Low Drawdown Trading Techniques - baoquankhu1.vn
Stocks to watch: Nurix Therapeutics sees relative strength rating jump to 83 - MSN
Cinctive Capital Management LP Raises Stock Holdings in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Short Squeeze: Can Nurix Therapeutics Inc grow without external fundingWeekly Stock Summary & Community Verified Trade Signals - baoquankhu1.vn
Nurix Therapeutics, Inc. $NRIX Stake Cut by Commodore Capital LP - MarketBeat
Nurix Therapeutics clears key benchmark, hitting 80-plus RS rating - MSN
Gains Report: Should I buy Nurix Therapeutics Inc stock now2026 Short Interest & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Surprises Report: Can Oak Woods Acquisition Corporation Equity Right disrupt its industry2026 Snapshot & Pattern Based Trade Signal System - baoquankhu1.vn
A Look At Nurix Therapeutics (NRIX) Valuation After Expanded Equity Distribution Agreement - Sahm
Understanding Momentum Shifts in (NRIX) - Stock Traders Daily
Market Moves: Will Nurix Therapeutics Inc announce a stock splitPortfolio Value Summary & Verified Technical Trade Signals - baoquankhu1.vn
Rhenman & Partners Asset Management AB Purchases 162,500 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Can Nurix Therapeutics Inc scale operations efficiently2025 Earnings Impact & Stepwise Trade Signal Guides - baoquankhu1.vn
Nurix Therapeutics Expands ATM Equity Offering Capacity - The Globe and Mail
Is Nurix Therapeutics Inc. stock a top momentum playJuly 2025 Levels & Scalable Portfolio Growth Ideas - Naître et grandir
Nurix Therapeutics amends equity distribution agreement for $413.65 million stock offering - Investing.com
Nurix Therapeutics adds $413.65M at-the-market equity facility with Piper Sandler - TradingView
Inflation Data: Whats the RSI of Nurix Therapeutics Inc stockPortfolio Value Report & Safe Investment Capital Preservation Plans - baoquankhu1.vn
ARK Investment Management LLC Has $13.96 Million Position in Nurix Therapeutics, Inc. $NRIX - MarketBeat
Nurix Therapeutics, Inc. $NRIX Stock Position Increased by Amova Asset Management Americas Inc. - MarketBeat
NRIX SEC FilingsNurix Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Handelsbanken Fonder AB Buys 240,000 Shares of Nurix Therapeutics, Inc. $NRIX - MarketBeat
Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX) - GuruFocus
Planned stock sale by Nurix (NRIX) chief legal officer disclosed - Stock Titan
Christine Ring sells RSU shares (NRIX) under 10b5-1 plan via Morgan Stanley - Stock Titan
Buybacks Report: What are Calix Incs growth levers2025 Bull vs Bear & AI Based Trade Execution Alerts - baoquankhu1.vn
Nurix Therapeutics (NRIX) Valuation Check After Recent Share Price Volatility And Rich Price To Sales Multiple - Yahoo Finance
NRIX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Avoiding Lag: Real-Time Signals in (NRIX) Movement - Stock Traders Daily
NRIX PE Ratio & Valuation, Is NRIX Overvalued - Intellectia AI
Redmile Group Increases Nurix Therapeutics Stake by 4.4M Shares - Intellectia AI
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million - The Motley Fool
Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Is There a 90% Upside Potential on the Horizon? - DirectorsTalk Interviews
Baker Bros discloses 7.2% Nurix (NRIX) ownership stake - Stock Titan
NRIX Technical Analysis & ETF Price Forecast - Intellectia AI
Discipline and Rules-Based Execution in NRIX Response - Stock Traders Daily
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Nurix Therapeutics Highlights STAT6, BTK and IRAK4 Degraders as Immunology Pipeline Gains Spotlight - MarketBeat
Does Nurix Therapeutics Inc. have a sustainable dividendJuly 2025 Institutional & Entry Point Confirmation Signals - mfd.ru
Is Nurix Therapeutics Inc. undervalued by DCF analysisQuarterly Portfolio Report & Accurate Entry/Exit Alerts - mfd.ru
What is the long term forecast for Nurix Therapeutics Inc. stockEarnings Summary Report & Reliable Trade Execution Plans - mfd.ru
Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Emerging Potential With 90% Upside - DirectorsTalk Interviews
NRIX: Degrader therapies advance in immunology, with key milestones expected for STAT6 and BTK programs - TradingView
Why Nurix Therapeutics Inc. stock remains resilient2025 Earnings Impact & Daily Technical Stock Forecast Reports - mfd.ru
Nurix (NASDAQ: NRIX) CFO awarded 93,750 options and 42,875 RSUs - Stock Titan
Ring Christine, chief legal officer at Nurix, sells $237k in NRIX stock - Investing.com Canada
Assessing Nurix Therapeutics (NRIX) Valuation After Revenue Growth Wider Loss And New Shelf Registration - simplywall.st
HC Wainwright remains a buy on Nurix Therapeutics (NRIX) - MSN
Nurix Therapeutics (NRIX) Is Down 7.4% After Pivotal Bexobrutideg Update and Wider 2025 Loss - Sahm
Nurix Therapeutics Inc Stock (NRIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.20%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):